Abstract: Disclosed is a coating composition for watch elements, comprising a binder, preferably a two-component polyurethane; one or more pigments, preferably in quantities from 19 to 58% by weight of pigments (based on total solids of the composition); at least one filler; a solvent or a solvent combination, preferably butyl acetate and/or ethyl lactate. optionally one or more commonly used additives, customary auxiliaries or combinations of them. Further disclosed are a kit-of-parts, a coating on a watch element, a process for coating a watch element and a watch obtainable by said process or comprising said coating.

Abstract: The present disclosure relates to the identification of a biomarker, consisting in a circulating miRNA, suitable for use in the diagnosis and prognosis of high-grade serous ovarian carcinoma (HGSOC), and to diagnostic kits for use in such diagnosis.

Abstract: Disclosed is a coating composition for watch elements, comprising a binder, preferably a two-component polyurethane; one or more pigments, preferably in quantities from 19 to 58% by weight of pigments (based on total solids of the composition); at least one filler; a solvent or a solvent combination, preferably butyl acetate and/or ethyl lactate. optionally one or more commonly used additives, customary auxiliaries or combinations of them. Further disclosed are a kit-of-parts, a coating on a watch element, a process for coating a watch element and a watch obtainable by said process or comprising said coating.

Abstract: The invention relates to a method comprising a step (E0) of forming a body provided with a cavity on a face of said body, a treatment step (E2) consisting of forming, on said body, at least one reinforced adhesion area which is at least partially outside the cavity, and a step (E3) of depositing composite material. During the deposition step (E3), the cavity is filled and the reinforced adhesion area is covered with the composite material.

Abstract: The invention relates to a method comprising a step (E0) of forming a body provided with a cavity on a face of said body, a treatment step (E2) consisting of forming, on said body, at least one reinforced adhesion area which is at least partially outside the cavity, and a step (E3) of depositing composite material. During the deposition step (E3), the cavity is filled and the reinforced adhesion area is covered with the composite material.

Abstract: The present disclosure relates to a surgical instrument for sampling molecules in an organ which can be accessed directly or via a surgical portal, including: a device for capturing the molecules, a stylet supporting the capture device, capable of entering the organ, a guide for inserting the stylet into the body as far as the organ, wherein the distal end of the guide is provided with a damping block intended to come to bear upon the organ.

Abstract: The present invention relates to a sampling instrument adapted for taking a sample in situ and in vivo or taking a sample ex vivo of a target tissue or body structure, in a maximum quantity of less than 10?6 g, the instrument comprising an elongated active member (10) with a distal operative end (11) having at least one retaining surface (12) arranged for contacting directly the target tissue or body structure, capturing and retaining molecules of the target tissue or body structure thereto.

Abstract: An in vitro diagnostic method for diagnosing a brain tumour belonging to the group formed by two types of tumours: ODGs and GBMs, and for identifying the type of tumour, the method includes the measurement of at least two ratios of the expression levels of miRNA pairs extracted from a biological sample originating from a patient suspected of presenting one of the above-mentioned brain tumours.

Abstract: The present application relates to the use of miRNAs as biomarkers in glioma diagnosis. It also relates to the use of miRNAs as biomarkers in glioblastoma and oligodendroglioma diagnosis.

Abstract: The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region.

Abstract: The present disclosure relates to a surgical instrument for sampling molecules in an organ which can be accessed directly or via a surgical portal, including: a device for capturing the molecules, a stylet supporting the capture device, capable of entering the organ, a guide for inserting the stylet into the body as far as the organ, wherein the distal end of the guide is provided with a damping block intended to come to bear upon the organ.

Abstract: The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region.

Abstract: The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region.

Abstract: The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region.

Abstract: The present invention relates to a sampling instrument adapted for taking a sample in situ and in vivo or taking a sample ex vivo of a target tissue or body structure, in a maximum quantity of less than 10?6 g, said instrument comprising an elongated active member (10) with a distal operative end i11) having at least one retaining surface (12) arranged for contacting directly said target tissue or body structure, capturing and retaining molecules of said target tissue or body structure thereto.

Abstract: A method for detecting presence or absence of a tumor in a mammal and/or its sensitivity to chemotherapies, including, on a biological sample from said mammal, detecting and/or quantifying: presence of an eEF1A1 protein, and/or presence of antibodies directed against an eEF1A1 protein or a fragment including at least one epitope of eEF1a1 protein, and/or presence of a MARK3 protein, and/or presence of antibodies directed against a MARK3 protein or a fragment comprising at least one epitope of the MARK3 protein.

Abstract: The invention relates to the use of morpholino-nucleosides of formula: in which R1 represents a nucleic base and R2 represents a group corresponding to one of the following formulae: —(CH2)n—NH2 —(CH2)n—SH —(CH2)n—COOH —(CH2)n—OH —(CH2)n—NH—R3 —(CH2)n—SR3 —(CH2)n—CO—R3 —(CH2)n—OR3 in which n is an interger ranging from 1 to 12 and R3 is a group derived from a label, from a protein, from an enzyme, from a fatty acid or from a peptide, as chain terminators in a process of DNA or RNA sequencing by the Sanger method, or for the labelling of DNA or RNA fragments.

Abstract: The invention relates to a novel method used for deter-mining the aggressiveness and/or invasiveness of a tumor. The invention also relates to a method for identifying an anticancer agent that makes it possible to reduce the aggressiveness and/or invasiveness of a tumor. The invention is based on the inventors' findings that vimentin produced by the cancer cells can be a marker of the aggressiveness and/or invasiveness of a tumor. This maker capacity is not associated with expression of the vimentin in the cancer cells but is with a post-translational transformation of this different protein according to the degree of aggressiveness and/or invasiveness.

Abstract: The invention relates to the use of morpholino-nucleosides of formula: in which R1 represents a nucleic base and R2 represents a group corresponding to one of the following formulae: —(CH2)n—NH2 —(CH2)n—SH —(CH2)n—COOH —(CH2)n—OH —(CH2)n—NH—R3 —(CH2)n—SR3 —(CH2)n—CO—R3 —(CH2)n—OR3 in which n is an interger ranging from 1 to 12 and R3 is a group derived from a label, from a protein, from an enzyme, from a fatty acid or from a peptide, as chain terminators in a process of DNA or RNA sequencing by the Sanger method, or for the labelling of DNA or RNA fragments.

Abstract: The invention relates to the use of morpholino-nucleosides of formula: in which R1 represents a nucleic base and R2 represents a group corresponding to one of the following formulae: —(CH2)n—NH2 —(CH2)n—SH —(CH2)n—COOH —(CH2)n—OH —(CH2)n—NH—R3 —(CH2)n—SR3 —(CH2)n—CO—R3 —(CH2)n—OR3 in which n is an interger ranging from 1 to 12 and R3 is a group derived from a label, from a protein, from an enzyme, from a fatty acid or from a peptide, as chain terminators in a process of DNA or RNA sequencing by the Sanger method, or for the labelling of DNA or RNA fragments.